Dr. S. Yousuf Zafar talks about the association between the body mass index of patients who are starting treatment for colorectal cancer and both the progression free survival and overall survival.
S. Yousuf Zafar, MD, Associate Professor of Medicine at Duke Cancer Institute, talks about the association between the body mass index (BMI) of patients who are starting treatment for colorectal cancer and both the progression free survival (PFS) and overall survival (OS).
Zafar says that while there was no link to be drawn between PFS and BMI in those patients, there was a connection between higher BMI and a better OS rate.
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More